Navigation Links
ChemoCentryx Reports Clinical Efficacy for CCX354, a Novel CCR1 Inhibitor in a Phase II Study in Patients with Rheumatoid Arthritis
Date:11/8/2011

pared to placebo at Week 12 (p=0.023).  ACR50, ACR70, DAS28-CRP, and ACR component results indicated greatest efficacy in the 200 mg daily dose group.  Decreases in bone turnover markers C-telopeptide (CTx), procollagen type I N-terminal propeptide (PINP), and osteocalcin were more pronounced in the CCX354-C groups compared to placebo, and reaching statistically significant improvements at many time points during the study. Clinical responders had higher plasma CCX354 concentrations than non-responders.  CCX354 was well tolerated by patients in this study.

Study DesignThis Phase II study named CARAT-2 (CCR1 Antagonist in Rheumatoid Arthritis Trial-2) was a 160-patient multinational, randomized, double-blind, placebo-controlled RA clinical trial.  Patients had moderate to severe RA, were on stable methotrexate treatment for at least 8 weeks, had >/= 8 swollen and tender joint counts, and CRP >/= 5 mg/L at study entry.  Patients received double-blind placebo twice daily (N=54), 100 mg CCX354 twice daily (N=53) or 200 mg CCX354 once daily (N=53) orally for 12 weeks.  Safety and tolerability were primary endpoints, and secondary endpoints included RA disease response measurements:  ACR, DAS28, CRP, and ESR, as well as bone turnover markers, CTx, PINP, and osteocalcin.

CCX354 and Rheumatoid Arthritis (RA)CCX354 is a potent and selective antagonist of CCR1, a chemokine receptor that drives the recruitment of certain inflammatory cells including populations of monocytes and macrophages into the joints of patients with RA.  By selectively blocking the CCR1 receptor, CCX354 is designed to reduce the infiltration of inflammatory cells into the joints of RA patients and inhibiting the inflammation, swelling, pain and associated joint destruction while minimizing the potential for off-target effects, thus providing a wider therapeutic window than currently approved thera
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ChemoCentryx Initiates Phase II Clinical Trial for CCX168, a Novel Small Molecule C5aR Antagonist for the Treatment of Vasculitis
2. ChemoCentryx Reports Novel CCR2 Antagonist Significantly Improves Kidney Function and Hyperglycemia in Models of Type 2 Diabetes
3. ChemoCentryx Initiates Phase I Clinical Trial of CCX832, the First Small Molecule Inhibitor of ChemR23
4. ChemoCentryx to Present at the 29th Annual J.P. Morgan Healthcare Conference
5. ChemoCentryx Reports Positive Phase I Results for CCX168, a Novel C5aR Antagonist, at the Annual American College of Rheumatology Meeting (ACR)
6. ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Treating Patients with Crohns Disease at the United European Gastroenterology Federation (UEGW) Meeting
7. ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
8. ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohns Disease at the Digestive Disease Week (DDW) 2010 Conference
9. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
10. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
11. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 17, 2014  Beamz Interactive, Inc. (OTCQB: BZIC), ... today announced that it has signed an agreement ... supplier of innovative prosthetic, orthotic and assistive technology ... the agreement, RSL Steeper will promote and supply ... for use within UK residential care facilities through ...
(Date:12/17/2014)... MARLBOROUGH, Mass. , Dec. 17, 2014 /PRNewswire/ ... a biotechnology company focused on discovering, developing and ... using RNA-targeted technologies, today announced completion of enrollment in ... results from the 3-month observations confirmed the 1-month ... year:  Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... addition of the "MEMS Gyroscopes Analog Devices ... report to their offering. ... for tactical grade applications made a lot of ... of reliability. They are now accepted in high-reliability ...
Breaking Medicine Technology:Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate Sensor Reverse Costing Analysis 2
... 04, 2007 /PRNewswire-FirstCall/ --,Bionovo, Inc.'s lead drug ... the treatment of hot flashes associated with ... in the company's,double-blind, placebo- controlled, randomized Phase ... moderate to severe hot flashes,per week were ...
... analyses of progression-free survival in,the SPARC Phase ... risk of disease progression for patients receiving,satraplatin. ... well as presence or absence of pain., ... and GPC Biotech AG today announced the ...
Cached Medicine Technology:Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in,Phase 2 Trial 2Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in,Phase 2 Trial 3Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in,Phase 2 Trial 4Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in,Phase 2 Trial 5Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 2Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 3Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 4Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 5Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 6Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 7
(Date:12/19/2014)... This is a professional and in-depth study on ... a focus on the Chinese market. The report provides ... manufacturers and is a valuable source of guidance and ... , Firstly, the report provides a basic overview of ... Then, the report explores the international and Chinese major ...
(Date:12/19/2014)... THURSDAY, Dec. 18, 2014 (HealthDay News) -- A new ... -- moderate to severe hot flashes and night sweats ... bones. Hot flashes are common during menopause, affecting ... menopause also affect women after menopause, since they then ... "Our findings suggest women who exhibit moderate or ...
(Date:12/19/2014)... Dec. 18, 2014 (HealthDay News) -- Traveling through the ... measles virus to three others within a four-hour time ... a new report shows. "The exposures in this ... rather than an international terminal, highlighting the fact that ... Jared Vega, an infectious disease specialist at the U.S. ...
(Date:12/17/2014)... Dr. Myo Nwe is the co-author of a ... Future” and co-founder of the Ace Medical Weight Loss Center ... a broad look at the industry of weight loss, and ... On film and in television shows, however, she says the ... aspects and played for basic laughs, which she believes impacts ...
(Date:12/17/2014)... 2014 A group of 127 scientists sent ... in reaction to a recent statement by the center that ... and derogated the efficacy of all brain exercises. , Signatories ... parts of the center’s statement critical of brain exercise companies ... also overstated its case, in a document it had entitled ...
Breaking Medicine News(10 mins):Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 2Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 3Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 4Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 5Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 6Health News:Severe Hot Flashes During Menopause May Raise Hip Fracture Risk Later: Study 2Health News:Arriving Now at Gate 42: Measles 2Health News:Arriving Now at Gate 42: Measles 3Health News:Obesity Should Not Be a Hollywood Punchline, Weight Loss Doc Says 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 3Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 4
... in CT scanner technology have made perfusion computed tomography ... suspected stroke. Now, researchers at Mayo Clinic are working ... other CT images. Mayo Clinic medical physicist Cynthia McCollough, ... related to CT dose reduction at the 52nd Annual ...
... and Massachusetts believe the Earth has been getting warmer ... percent and 84 percent, respectively), and large majorities favor ... new public opinion research by Professor Jon Krosnick, a ... at Stanford University. Following up on a ...
... A major breakthrough in how to target and destroy ... been made by researchers at Wake Forest University Baptist ... to target and destroy Glioblastoma multiforme (GBM) cells without ... possibilities in cancer research previously not known to be ...
... found a new mechanism that explains how certain immune ... or pathological antibodies such as those present in autoimmune ... published online in the September issue of Nature ... Professor of Medicine at Mount Sinai School of Medicine, ...
... By Ellin Holohan HealthDay Reporter , TUESDAY, ... rising, their quality of life is falling, according to new ... healthy days per year that Americans lose due to obesity ... about 7.5 in 1993 to 17 in 2008. Researchers ...
... HealthDay Reporter , MONDAY, Aug. 2 (HealthDay News) ... A new two-year study suggests that it may not ... about eating and exercise, people lost about the same amount ... or a traditional low-fat diet. "In general, dieters should ...
Cached Medicine News:Health News:Mayo Clinic researchers share latest findings in CT radiation dose reduction efforts 2Health News:New state surveys affirm Americans' support for government action on climate change 2Health News:New state surveys affirm Americans' support for government action on climate change 3Health News:Scientists develop 'designer protein,' opening new door in cancer research 2Health News:Scientists develop 'designer protein,' opening new door in cancer research 3Health News:New drug target for immune diseases discovered 2Health News:Weight Gain Eroding Americans' Quality of Life 2Health News:Weight Gain Eroding Americans' Quality of Life 3Health News:Low Carb-, Low-Fat Diets Tied for Long-Term Weight Loss 2Health News:Low Carb-, Low-Fat Diets Tied for Long-Term Weight Loss 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: